Q2 EPS Forecast for Phibro Animal Health Lowered by Analyst

Key Points

• Zacks Research has lowered its Q2 2026 earnings per share forecast for Phibro Animal Health to $0.62, down from a prior estimate of $0.67.
• Phibro Animal Health's stock currently holds a consensus rating of "Hold" with a price target of $28.40, based on evaluations from multiple analysts.
• CEO Jack Bendheim sold 14,080 shares of the company’s stock recently, a transaction that reduced his ownership by 23.67%.

Phibro Animal Health Corporation (NASDAQ:PAHC - Free Report) - Zacks Research dropped their Q2 2026 earnings per share (EPS) estimates for Phibro Animal Health in a note issued to investors on Wednesday, October 8th. Zacks Research analyst Team now forecasts that the company will post earnings of $0.62 per share for the quarter, down from their prior forecast of $0.67. Zacks Research has a "Strong-Buy" rating on the stock. The consensus estimate for Phibro Animal Health's current full-year earnings is $1.95 per share. Zacks Research also issued estimates for Phibro Animal Health's Q3 2026 earnings at $0.71 EPS, Q4 2026 earnings at $0.62 EPS, Q1 2027 earnings at $0.69 EPS, Q3 2027 earnings at $0.64 EPS, Q4 2027 earnings at $0.63 EPS, FY2027 earnings at $2.63 EPS and Q1 2028 earnings at $0.75 EPS.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last released its quarterly earnings results on Wednesday, August 27th. The company reported $0.57 earnings per share for the quarter, topping the consensus estimate of $0.52 by $0.05. The company had revenue of $378.70 million for the quarter, compared to analysts' expectations of $362.24 million. Phibro Animal Health had a return on equity of 32.14% and a net margin of 3.73%. Phibro Animal Health has set its FY 2026 guidance at 2.520-2.700 EPS.

Other analysts have also recently issued reports about the company. BNP Paribas Exane upgraded Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target on the stock in a report on Monday, June 16th. JPMorgan Chase & Co. upgraded Phibro Animal Health from a "neutral" rating to an "overweight" rating and boosted their price target for the stock from $25.00 to $35.00 in a report on Monday, July 7th. Weiss Ratings restated a "hold (c+)" rating on shares of Phibro Animal Health in a report on Saturday, September 27th. Bank of America boosted their price target on Phibro Animal Health from $19.00 to $27.00 and gave the stock an "underperform" rating in a report on Friday, August 29th. Finally, BNP Paribas upgraded Phibro Animal Health to a "hold" rating in a report on Monday, June 16th. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, four have given a Hold rating and two have issued a Sell rating to the company's stock. Based on data from MarketBeat, Phibro Animal Health currently has a consensus rating of "Hold" and a consensus price target of $28.40.

Phibro Animal Health Stock Performance

NASDAQ:PAHC opened at $37.11 on Thursday. The stock has a market cap of $1.50 billion, a P/E ratio of 31.45, a price-to-earnings-growth ratio of 1.14 and a beta of 0.83. The company has a current ratio of 2.76, a quick ratio of 1.25 and a debt-to-equity ratio of 2.46. The stock's 50-day moving average is $35.24 and its 200-day moving average is $27.54. Phibro Animal Health has a 1-year low of $16.16 and a 1-year high of $41.57.

Hedge Funds Weigh In On Phibro Animal Health

Several institutional investors have recently added to or reduced their stakes in the business. Squarepoint Ops LLC acquired a new position in shares of Phibro Animal Health during the second quarter worth approximately $813,000. Ranger Investment Management L.P. raised its position in shares of Phibro Animal Health by 101.1% during the second quarter. Ranger Investment Management L.P. now owns 357,970 shares of the company's stock worth $9,143,000 after purchasing an additional 179,975 shares during the period. State of Wyoming raised its position in shares of Phibro Animal Health by 148.8% during the second quarter. State of Wyoming now owns 6,608 shares of the company's stock worth $169,000 after purchasing an additional 3,952 shares during the period. Tower Research Capital LLC TRC raised its position in shares of Phibro Animal Health by 768.2% during the second quarter. Tower Research Capital LLC TRC now owns 4,610 shares of the company's stock worth $118,000 after purchasing an additional 4,079 shares during the period. Finally, State of Tennessee Department of Treasury raised its position in shares of Phibro Animal Health by 18.6% during the second quarter. State of Tennessee Department of Treasury now owns 26,743 shares of the company's stock worth $683,000 after purchasing an additional 4,200 shares during the period. 99.34% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Phibro Animal Health

In other Phibro Animal Health news, CEO Jack Bendheim sold 14,080 shares of the business's stock in a transaction that occurred on Tuesday, September 9th. The stock was sold at an average price of $40.33, for a total value of $567,846.40. Following the transaction, the chief executive officer directly owned 45,400 shares of the company's stock, valued at approximately $1,830,982. The trade was a 23.67% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold 24,622 shares of company stock valued at $995,893 over the last quarter. 50.13% of the stock is currently owned by insiders.

Phibro Animal Health Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Wednesday, September 24th. Shareholders of record on Wednesday, September 3rd were paid a $0.12 dividend. The ex-dividend date of this dividend was Wednesday, September 3rd. This represents a $0.48 annualized dividend and a yield of 1.3%. Phibro Animal Health's payout ratio is 40.68%.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.